An Open Label Trial of Dianhydrogalactitol (VAL-083) and Radiation Therapy in Treatment of Newly Diagnosed GBM Patients With An Unmethylated Promoter of the Methylguanine-DNA Methyltransferase (MGMT) Gene

Trial Profile

An Open Label Trial of Dianhydrogalactitol (VAL-083) and Radiation Therapy in Treatment of Newly Diagnosed GBM Patients With An Unmethylated Promoter of the Methylguanine-DNA Methyltransferase (MGMT) Gene

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Dianhydrogalactitol (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Del Mar Pharmaceuticals; Guangxi Wuzhou Pharmaceutical
  • Most Recent Events

    • 25 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
    • 24 Jul 2017 The Human Genetic Resources Administration of China (HGRAC), has approved the Company's application to initiate a Phase 2 study of VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM).
    • 18 May 2017 According to a DelMar Pharmaceuticals media release, the company has received ethics committee approval, retained a contract research organization, and submitted an application to the China Office of Human Genetic Resources Authority (OHGRA) to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top